Dallas, Texas 04/01/2014 (FINANCIALSTRENDS) – Synthetic Biologics Inc (NYSEMKT:SYN) has been working on the clinical data of its specialty product for some time. With the results of the trials pending announcement, investor sentiment and trader sentiment appear to be bullish.
Synthetic Biologics Inc (NYSEMKT:SYN) has reported that the Phase II trials for Multiple Sclerosis is already underway and the company is likely to see high traction based on the results.
Synthetic Biologics Inc (NYSEMKT:SYN) holds a market capital of $151.38 million. The company at previous opening of session saw $2.56 and infra-day trading range of $2.64 and $2.56. The 52- week average for this producer ranges between prices as high as $3.64 and low of $0.95. EPS reported is -0.47. Outstanding shares are 58 million. Beta is 1.68.
Synthetic Biologics Inc(NYSEMKT:SYN) has been working on a cure for Multiple Sclerosis, which is not caused by external factors but due to innate nature of the body. It is found that, in certain people, a condition called as auto-immune which is the condition when the immune system, will begin to function to fight disease-causing attacks, even though no such external factor is in play. Multiple sclerosis is considered as a genetically triggered condition caused when the central nervous system is badly affected. This causes much of the routine and critical function features of the body being disrupted. This leads to a the immune cells of the body actually attack a part of the nerve cell called as Myelin Sheath. This sheath is responsible for the transmission of signals of the nervous system. The disruption leads to numbness and sometimes paralysis and even blindness in affected people.
Synthetic Biologics Inc(NYSEMKT:SYN), much like other company’s with the clinical results due any time, for its drugs- Trimesta as well as Copaxone. The company has announced that it will see the use of its drugs in pregnant patients and will relate the results to the use of this hormone.